Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

Inclusion criteria

• Individuals age 18-70 years old with eyelid dermatitis for at least two months
• Failure of at least one topical prescription cream for the eyelid dermatitis (steroid, pimecrolimus, tacrolimus, crisaborole, or ruxolitinib)
• Women of reproductive potential must agree to using effective contraception during treatment and for 4 weeks following the final dose of Upadacitinib.
• Willing and able participants that provide informed consent
• Willing and able participants that comply with study activities

Exclusion criteria

• Self-reported history of allergic response to upadacitinib
• Subject with self-reported history of heart disease, stroke, or neurological conditions
• Currently taking topical medications for eyelid dermatitis within one week of starting study drug
• Women who are pregnant, nursing, or who may become pregnant during the study
• Non-English-speaking subjects
• Patients with an active serious infection
• Patients with active TB or latent TB, patients should be tested for TB prior to upadacitinib treatment.
• Patients with active HBV/HCV or abnormal lab ranges, Lab Data: Hb<8g/dL, ALC<500 cells/mm3 and ANC <1000 cells/mm3
• Patients with a history of malignancy within the last 5 years other than successfully treated NMSC.